The capture: lawful and regulatory certainty is small. Retatrutide was never around the FDA drug scarcity checklist (since it was never ever permitted), so compounders presenting it run beneath additional tenuous legal framing than those who handled semaglutide or tirzepatide throughout the 2023–202